FDA Approves Moderna’s mRNA Flu Vaccine for Adults 50 and Older
The U.S. Food and Drug Administration has approved Moderna's new mRNA-based flu vaccine, mFlusiva, for adults aged 50 and older. This new vaccine utilizes the same technology used in COVID-19 vaccines and is expected to be available soon at select…
Philadelphia, PA, August 6, 2026 —
The U.S. Food and Drug Administration (FDA) has granted approval for Moderna’s new messenger RNA (mRNA)-based flu vaccine, known as mFlusiva. The vaccine is indicated for use in adults aged 50 years and older.
mFlusiva employs the same mRNA technology that has been utilized in the development of COVID-19 vaccines. This approval introduces a new option for influenza prevention, with a specific focus on an age group that is often more susceptible to severe outcomes from the flu.
According to the information provided, the vaccine is anticipated to become available in the near future through select retail locations. The availability of mFlusiva is expected to broaden the choices for individuals seeking protection against the seasonal flu, particularly for older adults who face a higher risk of complications from influenza infection.
Story summarized from the original created by LAURAN NEERGAARD on www.inquirer.com, see more information here.
